Table 1 Baseline characteristics
Characteristic | IP/IV arm (N = 106) | IV arm (N = 109) | P valuea |
|---|---|---|---|
Median age (range) | 54 years | 57 years | 0.517 |
(35–78) | (40–75) | ||
FIGO stage | 0.706 | ||
Stage IIIC | 83 (78.3%) | 83 (76.1%) | |
Stage IV | 23 (21.7%) | 26 (23.9%) | |
Primary tumour | 0.336 | ||
Epithelial ovarian cancer | 96 (90.6%) | 99 (90.8%) | |
Fallopian tube cancer | 9 (8.5%) | 6 (5.5%) | |
Primary peritoneal cancer | 1 (0.9%) | 4 (3.7%) | |
Histology | 0.537 | ||
Serous | 99 (93.4%) | 101 (92.7%) | |
Endometrioid | 1 (0.9%) | 2 (1.8%) | |
Clear cell | 1 (0.9%) | 4 (3.7%) | |
Undifferentiated | 4 (3.8%) | 2 (1.8%) | |
Others | 1 (0.9%) | 0 (0%) | |
Grade | 0.773 | ||
Low | 2 (1.9%) | 3 (2.8%) | |
High | 104 (98.1%) | 104 (95.4%) | |
NA | 0 (0%) | 2 (1.8%) | |
ECOG performance status | 0.580 | ||
0 | 44 (41.5%) | 40 (36.7%) | |
1 | 58 (54.7%) | 62 (56.9%) | |
2 | 4 (3.8%) | 7 (6.4%) | |
ASA Score | 1.000 | ||
1 | 62 (58.5%) | 63 (57.8%) | |
2 | 43 (40.6%) | 46 (41.3%) | |
3 | 1 (0.9%) | 1 (0.9%) | |
Preoperative CA125 measurement | 0.946 | ||
Median serum level | 870.5 U/ml | 928.0 U/ml | |
(range) | (13.6–25210.9) | (47.1–72090.3) | |
Ascites | 0.186 | ||
Median volume | 1000 ml | 800 ml | |
(range) | (0–8000) | (0–7000) | |
Neoadjuvant chemotherapy | 0.171 | ||
Yes | 14 (13.2%) | 22 (20.2%) | |
No | 92 (86.8%) | 87 (79.8%) | |
Residual disease in the whole abdomen | 0.601 | ||
0 cm | 38 (35.8%) | 40 (36.7%) | |
0.1–0.5 cm | 56 (52.8%) | 52 (47.7%) | |
0.5–1 cm | 12 (11.3%) | 17 (15.6%) |
